Vertex Pharmaceuticals develops and commercializes therapies for cystic fibrosis (CF) and other diseases. Products include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The pipeline includes VX-522 for CF, VX-548 for pain, Exa-cel for sickle cell disease and beta thalassemia, and others. Inaxaplin treats APOL1-mediated glomerulosclerosis and hypertension. Vertex also develops treatments for Type 1 Diabetes, cancer, and Duchenne muscular dystrophy with various partners. The company sells products to specialty pharmacies and distributors in the US and abroad. Founded in 1989, Vertex is headquartered in Boston, Massachusetts.
Indicator | Value |
---|---|
PER | 100.0 |
EV/EBITDA | 23.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | -0.6 |